Study of compound matrine injection on preventing hepatic lesion caused by chemotherapy
10.3760/cma.j.issn.1006-9801.2010.04.014
- VernacularTitle:复方苦参注射液在预防化疗所致肝损害方面的研究
- Author:
Xiaoqiu CHEN
;
Nannan LIU
;
Donglan SHEN
- Publication Type:Journal Article
- Keywords:
Drug therapy;
Antaneoplastic combined chemotherapy protocols;
Liver diseases;
Protective agents
- From:
Cancer Research and Clinic
2010;22(4):261-263
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the preventive effect of compound matrine injection on hepatic lesion caused by chemotherapy. Methods 178 patients after gastric and colorectal cancer resection were enrolled into three groups randomly. 56 patients in group A received MFOLFOX6 regimen treatment only, 62 patients in group B received both normal treatment and combined compound matrine injection,60 patients in group C received both normal treatment and glutathione. The change of liver function were observed. Results There was no the hepatotoxicity of Ⅲ-Ⅳ degree in all groups;the incidence of bilirubin and transaminase increasing in group B and C was significantly lower than that group A(P ＜0.05), but the incidence of ALP/GGT increasing showing no significant difference among the three groups; 72.7 % of the incidence of hepatic lesion in group A happened firstly before the seventh cycle,it was 27.3 % and 33.3 % respectively in group B and group C, the time of the emerging of hepatotoxicity in group B and C was markedly delayed than that group A (P ＜0.05); there was not significant difference between group B and group C in both bilirubin and transaminase increasing and the time of the emerging of hepatotoxicity (P ＞0.05). Conclusion Compound matrine injection can prevent and postpone the happening of hepatic lesion caused by adjuvant chemotherapy after digestive tract cancer resection, The result is equal to glutathione. Compound matrine injection also has antineoplastic effects, so the clinical superiority is more obvious.
